Lexicon Pharmaceuticals Inc <LXRX.OQ> expected to post a loss of 8 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc LXRX.OQ LXRX.O is expected to show a rise in quarterly revenue when it reports results on August 6 for the period ending June 30 2025
The The Woodlands Texas-based company is expected to report a 195.5% increase in revenue to $4.868 million from $1.65 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
LSEG's mean analyst estimate for Lexicon Pharmaceuticals Inc is for a loss of 8 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc is $1.20, about 10.8% above its last closing price of $1.07
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.10 | -0.10 | -0.07 | Beat | 28.2 |
Dec. 31 2025 | -0.13 | -0.13 | -0.09 | Beat | 29.3 |
Sep. 30 2024 | -0.17 | -0.16 | -0.18 | Missed | -9.4 |
Jun. 30 2024 | -0.19 | -0.19 | -0.17 | Beat | 9.9 |
Mar. 31 2024 | -0.20 | -0.20 | -0.20 | Met | -1.3 |
Dec. 31 2023 | -0.22 | -0.22 | -0.20 | Beat | 7.9 |
Sep. 30 2023 | -0.21 | -0.21 | -0.21 | Met | 2.2 |
Jun. 30 2023 | -0.17 | -0.17 | -0.22 | Missed | -25.9 |
This summary was machine generated August 4 at 12:45 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
